Compare Adaptive Biotechnologies Corp (ADPT) vs Marriott International Inc (MAR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Marriott International Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.09 (market cap $3.33B), while Marriott International Inc trades at $373.39 (market cap $100.40B). The key difference: Marriott International Inc is far larger — about 30.2× Adaptive Biotechnologies Corp's market cap, and Marriott International Inc pays a 0.77% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | MAR | |
|---|---|---|
Market Cap | $3.33B | $100.40B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $402.54 |
52-Week Low | $10.24 | $255.35 |
Enterprise Value | $3.19B | $117.35B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Marriott International (MAR) trades at $380.75, up 2.09% today, near its consensus price target of $386.42. The stock shows a bullish technical trend with strong moving averages, while fundamentals reveal robust revenue growth to $26.19B in 2025 and a net income margin of 9.72%. Recent developments include a strategic beverage agreement with Coca-Cola and the launch of an AI-powered travel search tool, Ask Bonvoy, enhancing its digital offerings.
The outlook for MAR is positive with analyst consensus leaning bullish (44% Buy ratings), though high debt levels and owner disputes over the Bonvoy loyalty program pose risks. Earnings beats in recent quarters support growth, but valuation metrics like a P/E of 39.76 suggest premium pricing. Investors should weigh solid operational cash flow against escalating liabilities for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
